See the DrugPatentWatch profile for Fondaparinux
Specific patent information concerning ocular infections related to fondaparinux is not readily available in the provided context.
What is Fondaparinux Used For?
Fondaparinux is a synthetic pentasaccharide anticoagulant. It is used for the prevention and treatment of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in the treatment of acute venous thromboembolism in patients with heparin-induced thrombocytopenia (HIT) [1].
How Does Fondaparinux Work?
Fondaparinux selectively inhibits activated factor X (FXa), a key enzyme in the blood coagulation cascade. By inhibiting FXa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and clot formation [1].
When Does Fondaparinux's Main Patent Expire?
The primary patent for fondaparinux has expired, allowing for the development and potential market entry of generic versions. This patent expiry is a significant factor for the pharmaceutical industry and healthcare providers, potentially leading to cost savings [2].
Are There Other Patents Related to Fondaparinux?
While the main patent for the fondaparinux molecule has expired, pharmaceutical companies may hold secondary patents related to specific formulations, manufacturing processes, or new indications. DrugPatentWatch.com tracks such patents and their expiry dates, which can impact market exclusivity for different applications of the drug [2]. Information regarding patents specifically for ocular infections linked to fondaparinux is not explicitly detailed.
What are the Side Effects of Fondaparinux?
The most common side effect associated with fondaparinux is bleeding. Other reported side effects can include anemia, nausea, and headache [1]. Concerns about specific side effects, especially in relation to less common applications like ocular infections, would require detailed clinical data or specific product information.